Gläser Timothy, Böhringer Daniel, Evers Charlotte, Keye Philip, Reinhard Thomas, Lübke Jan
Eye Center, University Hospital Freiburg, 79106 Freiburg im Breisgau, Germany.
J Clin Med. 2024 May 11;13(10):2831. doi: 10.3390/jcm13102831.
This retrospective study evaluated the safety and efficacy of the new minimally invasive MINIject implant placed in the suprachoroidal space. The aim was to assess its impact on intraocular pressure (IOP) reduction and complication rate. 18 eyes from 18 patients with insufficiently controlled glaucoma received the implant using topical medications. Outcomes were changes in IOP, change in IOP medication, need for other glaucoma surgery, and rate of adverse events. IOP reduced by 15% ( < 0.05) following MINIject implantation. IOP medication decreased from 3 to 1 agent ( < 0.05). Four patients (22%) required other glaucoma surgery while we did not observe any clinically relevant adverse event. This retrospective study indicates that MINIject implants may be a safe and effective means of reducing IOP together with a reduction in IOP medications in most patients. Larger prospective studies with longer follow-ups are necessary to confirm our results, though.
这项回顾性研究评估了植入脉络膜上腔的新型微创MINIject植入物的安全性和有效性。目的是评估其对降低眼压(IOP)和并发症发生率的影响。18例青光眼控制不佳的患者的18只眼睛使用局部药物接受了该植入物。结果包括眼压的变化、眼压药物的变化、是否需要其他青光眼手术以及不良事件发生率。MINIject植入后眼压降低了15%(P<0.05)。眼压药物从3种减少到1种(P<0.05)。4例患者(22%)需要进行其他青光眼手术,同时我们未观察到任何临床相关的不良事件。这项回顾性研究表明,MINIject植入物可能是大多数患者降低眼压以及减少眼压药物使用的一种安全有效的方法。不过,需要进行更大规模、随访时间更长的前瞻性研究来证实我们的结果。